Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Therapeutics, Neon Therapeutics Enter Research Collaboration

NEW YORK (GenomeWeb) – CRISPR Therapeutics and Neon Therapeutics said today that they have entered a research collaboration to explore using a combination of each company's proprietary technologies to develop novel T cell therapies.

Headquartered in Basel, Switzerland, CRISPR Therapeutics is a gene-editing company focused on developing gene-based medicines for serious diseases using a proprietary CRISPR/Cas9 gene-editing platform.

Neon Therapeutics is an immune-oncology firm developing novel cancer drugs that leverage neoantigen biology, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. The company's current lead program is a personalized neoantigen vaccine now in multiple clinical trials.

"We look forward to applying our proprietary CRISPR/Cas9 technologies in a variety of ways to generate potent T cell therapies directed against neoantigens," CRISPR Therapeutics President Samarth Kulkarni said in a statement.